**CDKN2A/p16**

Associated cancers with enough data for site:

1. Melanoma
2. Pancreatic

Reviewed but not enough data for site/ controversy over risk

Secondary cancers to review later:

From Ambry Genetics (http://www.ambrygen.com/tests/cdkn2a-and-cdk4-testing):

CDKN2A  
*CDKN2A* mutations contribute to 10-39% of hereditary melanoma; the more members of the same family have melanoma, the more likely it is due to a *CDKN2A* mutation.2, 5, 8-11 The majority of the information regarding mutations in *CDKN2A* refers to those affecting the p16 transcript. Mutations affecting the p14 transcript are rare and, hence, not much information is known about the clinical features.8, 12-14 It is estimated that individuals with a *CDKN2A* mutation have an approximate 28-67% lifetime risk of developing melanoma, with penetrance estimates varying widely based on study design and geographic region.4, 6-8 Those with a *CDKN2A* mutation also have an approximate 17-25% lifetime risk of developing pancreatic cancer; however, recent reports suggest this risk may be as high as 58%, and are potentially higher in smokers.